[1] WHITE DL, KANWAL F, EL-SERAG HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic revie[J]. Clin Gastroenterol Hepatol, 2012,10(12):1342-1359. [2] MUSSO G, GAMBINO R, CASSADER M, et al. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity[J]. Ann Med, 2011,43(8):617-649. [3] 侯素青,辛永宁,宣世英.基于体检档案对沿海地区人群脂肪性肝病发病现状及影响因素初探[J].中国医院统计,2013,20(3):199-201. [4] GOSSARD AA, LINDOR KD. Current therapies for nonalcoholic fatty liver disease[J]. Drugs Today(Barc),2011,47(12):915-922. [5] 王玉衡,张海鸥.非酒精性脂肪肝的中医药治疗进展[J].中医药通报,2014(04):64-66. [6] ROBBINS GR, WEN H, TING JPY. Inflammasomes and Metabolic Disorders: Old Genes in Modern Diseases[J]. Molecular Cell, 2014,54(2):297-308. [7] KIM JJ, JO EK. NLRP3 Inflammasome and Host Protection against Bacterial Infection[J]. Journal of Korean Medical Science, 2013,28(10):1415-1423. [8] 高小娟,林苏,朱月永.NLRP3炎症小体与非酒精性脂肪性肝病[J].中华肝脏病杂志,2016,24(12):956-960. [9] 中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南:2010年修订版[J].中华肝脏病杂志,2010,18(3):167-170. [10]DAY CP, JAMES OF. Steatohepatitis: a tale of two ″hits″?[J]. Gastroenterology, 1998,114(4):842-845. [11]DAS SK, BALAKRISHNAN V. Role of cytokines in the pathogenesis of non-alcoholic fatty liver disease[J]. Indian J Clin Biochem, 2011,26(2):202-209. [12]HAUKELAND JW, DAMAS JK, KONOPSKI Z, et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2[J]. Journal of Hepatology, 2006,44(6):1167-1174. [13]王晓彤,韩涛.NLRP3炎症小体在肝脏疾病发病中的作用研究进展[J].实用肝脏病杂志,2014(5):546-549. [14]WREE A, EGUCHI A, MCGEOUGH MD, et al. NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation and fibrosis[J]. Hepatology, 2014,59(3):898. [15]STIENSTRA R, VAN DIEPEN JA, TACK CJ, et al. Inflammasome is a central player in the induction of obesity and insulin resistance[J]. Proceedings of the National Academy of Sciences of the United States of America, 2011,108(37):15324. [16]MENG N, XIA M, LU YQ, et al. Activation of NLRP3 inflammasomes in mouse hepatic stellate cells duringSchistosoma J.infection[J]. Oncotarget, 2016,7(26):39316-39331. [17]许勇,陶颖,苟小军.非酒精性脂肪肝中医病因病机探析[J].中华中医药学刊,2016(11):2586-2589. [18]郝丽红.强肝胶囊对非酒精性脂肪肝患者临床症状改善情况及肝功能的影响[J].实用临床医药杂志,2015,19(1):126-127. [19]欧强, 徐燕华, 曲立娟,等. 强肝胶囊对非酒精性脂肪性肝病患者胰岛素抵抗指数和肝纤维化评分的影响[J].临床肝胆病杂志, 2016,32(10):1951-1954. [20]白丽华.强肝胶囊联合二甲双胍治疗非酒精性脂肪肝疗效观察[J].现代中西医结合杂志,2016,25(15):1667-1668. [21]HAITAO WEN, DENIS GRIS, YU LEI, et al. Fatty acid-induced NLRP3-PYCARD inflammasome activation interferes with insulin signaling[J]. Nature Immunology, 2011, 12(5):408. [22]强乐,郑淑予,薛梦雯.NALP3炎症小体促进高脂血症发展[J].第二军医大学学报,2014,35(S1):15-16. [23]MATSUZAKA T, ATSUMI A, MATSUMORI R, et al. Elovl6 promotes nonalcoholic steatohepatitis[J]. Hepatology, 2012,56(6):2199-2208. [24]NOV O, SHAPIRO H, OVADIA H, et al. Interleukin-1β Regulates Fat-Liver Crosstalk in Obesity by Auto-Paracrine Modulation of Adipose Tissue Inflammation and Expandability[J]. Plos One, 2013,8(1):e53626. [25]MIURA K, KODAMA Y, INOKUCHI S, et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice[J]. Gastroenterology, 2010,139(1):323.
